Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.

ABSTRACT: There are four solid tumors with common screening options in the average-risk population aged 21 to 75 years (breast, cervical, colorectal, and, based on personalized risk assessment, prostate), but many cancers lack recommended population screening and are often detected at advanced stages when mortality is high. Blood-based multi-cancer early detection tests have the potential to improve cancer mortality through additional population screening. Reported here is a post-hoc analysis from the third Circulating Cell-free Genome Atlas substudy to examine multi-cancer early detection test performance in solid tumors with and without population screening recommendations and in hematologic malignancies. Participants with cancer in the third Circulating Cell-free Genome Atlas substudy analysis we

SUBMITTER: Shao SH 

PROVIDER: S-EPMC10248281 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature